Orforglipron vs Palmitoyl Dipeptide-6
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
OrforglipronSkin & CosmeticAnti-Aging & Longevity
Palmitoyl Dipeptide-6- Summary
- Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
- Palmitoyl Dipeptide-6 is a synthetic dipeptide (lysine-threonine) with a palmitoyl fatty acid tail, designed to penetrate the skin barrier and stimulate the extracellular matrix components essential for skin firmness. It activates fibronectin and type IV collagen synthesis, improving skin density and firmness particularly in mature or sagging skin.
- Half-Life
- ~12 hours (once-daily oral dosing)
- Not applicable (topical)
- Admin Route
- Oral
- Topical
- Research
- —
- —
- Typical Dose
- 12 mg → 24 mg → 36 mg → 45 mg
- 0.005–0.05% in formulation
- Frequency
- Once daily
- Once or twice daily
- Key Benefits
- Oral pill — no injections required
- Once-daily dosing without food restrictions (unlike oral semaglutide)
- Up to 9.4% body weight reduction in Phase 2 at 36 weeks
- Significant HbA1c reduction in type 2 diabetes trials
- Small-molecule stability — no cold chain requirements
- Broadens access for injection-averse patients
- Potential class-defining convenience advantage over injectable GLP-1s
- Increases skin firmness and density
- Stimulates fibronectin and collagen IV production
- Strengthens the dermal-epidermal junction
- Reduces skin sagging in mature skin
- Improves skin texture and smoothness
- Supports extracellular matrix integrity
- Side Effects
- Nausea (most common, dose-dependent)
- Vomiting
- Diarrhea
- Decreased appetite
- +2 more
- Generally well-tolerated
- Rare mild skin irritation in sensitive individuals
- No known systemic effects at cosmetic concentrations
- Stacks With
- —
- —